The purpose of anti-epileptic treatment is to stop or minimize the number of crises with the least possible side effects.

Some medicines in some patients cause side effects, while some medications may not be effective in some patients.

Often, antiepileptic medication is life-long and can have a significant effect on the quality of life of the individual.

The majority of antiepileptic medicines are mainly metabolised by cytochrome P450 enzymes CYP2C9, CYP2C19 and CYP3A4 / 5.

The polymorphisms of CYP2C9, CYP2C19 and CYP3A4 / 5 enzymes are often associated with the occurrence of more than expected side effects or pharmacotherapy inefficiency and consequently failure.

The scientific findings show that both the efficacy and the occurrence of adverse medicine reactions depend to a large extent on genetic factors.

The identification of polymorphisms of CYP2C9, CYP2C19, CYP3A4 / 5 enzymes involved in the metabolism of antiepileptic medicines in patients onset or already treated with antiepileptic medicines and presenting adverse reactions or non-response to treatment is an additional useful information in the selection of the appropriate treatment for the patient.